Earnings ·
Reports Q3 net loss of $0.07 per share as cash falls to $11.7 million
GANXGain Therapeutics, Inc.
Gain Therapeutics reported a third-quarter net loss of $0.07 per share, narrowing from $0.15 in the prior-year period. Research and development expenses dropped by $1.4 million to $1.4 million due to lower costs for rexaceract and personnel savings, while general and administrative expenses decreased slightly to $1.8 million. Cash and cash equivalents declined to $11.7 million from $20.8 million at year-end 2025. The company highlighted long-term data showing stability in Parkinson's disease motor symptoms after 12 months of rexaceract treatment and expects its Phase 2 trial to begin in Q1 2027. Gain Therapeutics is a clinical-stage biotechnology company developing allosteric small molecule therapies for neurodegenerative diseases.